Jeremy Grantham Supernus Pharmaceuticals, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$24.15 - $31.45 $528,885 - $688,755	-21,900 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$17.7 - $25.81 $210,630 - $307,139	11,900 Added 119.0%	21,900 $551,000
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $202,000 - $250,500	10,000 New	10,000 $208,000
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $298,480 - $349,320	-8,200 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	8,200	8,200 $353,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.